Novigenix SA is a precision medicine biotechnology company based in Lausanne, Switzerland with a dedicated team of 18 full-time employees and cutting-edge facilities. We specialize in liquid biopsy (LBx) RNA analytics, combining advanced molecular technologies and artificial intelligence to deliver precision immune intelligence that transforms clinical development of novel therapeutics and patient care. Our groundbreaking solution, LITOSeek, is the first AI-enabled Liquid ImmunoTranscriptOmics platform designed for precise and predictive patient profiling. By integrating next-generation sequencing (NGS), artificial intelligence, and a multiomics approach, LITOSeek deciphers systemic immune landscapes using blood RNA biomarkers. This comprehensive analysis incorporates genomics, proteomics, methylation, and transcriptomics to generate robust, patient-specific insights.LITOSeek addresses critical limitations in oncology, where current tumor-centric approaches like ctDNA analysis fail to assess the host immune response or predict clinical benefit accurately. By agnostically analyzing the systemic immune landscape, LITOSeek provides unparalleled predictive power and mechanistic insights into patient responses, far surpassing traditional methods reliant on limited immune cell panels. Validated in metastatic bladder cancer patients undergoing second-line immunotherapy, the platform demonstrated unprecedented predictive capability by consistently identifying all clinical responders, and revealed resistance mechanisms in non-responders. EIC Accelerator support will enable Novigenix to optimize production costs, advance the technology to reduce turnaround time, and broaden market access through a SaaS model targeting biopharma and clinical markets. This support will accelerate LITOSeeks path to mass adoption, unlocking large-scale revenue potential and allowing us to scale rapidly across multiple markets in precision medicine, drug development, and diagnostics.